Last reviewed · How we verify
Capecitabine during all Radiotherapy period
Capecitabine during all Radiotherapy period is a Antimetabolite Small molecule drug developed by Grupo Espanol Multidisciplinario del Cancer Digestivo. It is currently in Phase 2 development for Colorectal cancer, Breast cancer. Also known as: Xeloda.
Capecitabine is a thymidylate synthase inhibitor.
Capecitabine is a thymidylate synthase inhibitor. Used for Colorectal cancer, Breast cancer.
At a glance
| Generic name | Capecitabine during all Radiotherapy period |
|---|---|
| Also known as | Xeloda |
| Sponsor | Grupo Espanol Multidisciplinario del Cancer Digestivo |
| Drug class | Antimetabolite |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Capecitabine is a prodrug that is converted to 5-fluorouracil (5-FU) in the body, which then inhibits thymidylate synthase, an enzyme involved in DNA synthesis.
Approved indications
- Colorectal cancer
- Breast cancer
Common side effects
- Hand-foot syndrome
- Diarrhea
- Fatigue
Key clinical trials
- Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer (PHASE4)
- PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery (PHASE2, PHASE3)
- Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer (PHASE1)
- Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum (PHASE2)
- Concurrent Chemo-Radiotherapy Versus Radiotherapy With Boost in Locally Advanced Unresectable Rectal Cancers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine during all Radiotherapy period CI brief — competitive landscape report
- Capecitabine during all Radiotherapy period updates RSS · CI watch RSS
- Grupo Espanol Multidisciplinario del Cancer Digestivo portfolio CI
Frequently asked questions about Capecitabine during all Radiotherapy period
What is Capecitabine during all Radiotherapy period?
How does Capecitabine during all Radiotherapy period work?
What is Capecitabine during all Radiotherapy period used for?
Who makes Capecitabine during all Radiotherapy period?
Is Capecitabine during all Radiotherapy period also known as anything else?
What drug class is Capecitabine during all Radiotherapy period in?
What development phase is Capecitabine during all Radiotherapy period in?
What are the side effects of Capecitabine during all Radiotherapy period?
What does Capecitabine during all Radiotherapy period target?
Related
- Drug class: All Antimetabolite drugs
- Target: All drugs targeting Thymidylate synthase
- Manufacturer: Grupo Espanol Multidisciplinario del Cancer Digestivo — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Colorectal cancer
- Indication: Drugs for Breast cancer
- Also known as: Xeloda
- Compare: Capecitabine during all Radiotherapy period vs similar drugs
- Pricing: Capecitabine during all Radiotherapy period cost, discount & access